Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges (2024 - 2025)

Arrowhead Pharmaceuticals' Amortization of Deferred Charges history spans 2 years, with the latest figure at $14.9 million for Q4 2025.

For Q4 2025, Amortization of Deferred Charges fell 8.17% year-over-year to $14.9 million; the TTM value through Dec 2025 reached $62.0 million, up 142.68%, while the annual FY2025 figure was $63.3 million, 579.67% up from the prior year.
Amortization of Deferred Charges reached $14.9 million in Q4 2025 per ARWR's latest filing, up from $14.6 million in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $16.4 million in Q2 2025 to a low of $9.3 million in Q3 2024.